{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T01:31:40Z","timestamp":1792373500138,"version":"4.4.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T00:00:00Z","timestamp":1621296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T00:00:00Z","timestamp":1621296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81903462"],"award-info":[{"award-number":["81903462"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073703"],"award-info":[{"award-number":["82073703"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2018M641694"],"award-info":[{"award-number":["2018M641694"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1038\/s41375-021-01283-5","type":"journal-article","created":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T05:02:53Z","timestamp":1621314173000},"page":"2862-2874","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Small-molecule inhibitor targeting the Hsp70-Bim protein\u2013protein interaction in CML cells overcomes BCR-ABL-independent TKI resistance"],"prefix":"10.1038","volume":"35","author":[{"given":"Ting","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yafei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuguang","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongwei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziqian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghai","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangkui","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Bonnette","family":"Uwituze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2774-2384","authenticated-orcid":false,"given":"Zhichao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,18]]},"reference":[{"key":"1283_CR1","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/nrc1567","volume":"5","author":"R Ren","year":"2005","unstructured":"Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer. 2005;5:172\u201383.","journal-title":"Nat Rev Cancer"},{"key":"1283_CR2","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1007\/BF02981952","volume":"73","author":"M Sattler","year":"2001","unstructured":"Sattler M, Griffin JD. Mechanisms of transformation by the BCR\/ABL oncogene. Int J Hematol. 2001;73:278\u201391.","journal-title":"Int J Hematol"},{"key":"1283_CR3","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/nchembio.775","volume":"8","author":"O Hantschel","year":"2012","unstructured":"Hantschel O, Warsch W, Eckelhart E, Kaupe I, Grebien F, Wagner KU, et al. BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia. Nat Chem Biol. 2012;8:285\u201393.","journal-title":"Nat Chem Biol"},{"key":"1283_CR4","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/emmm.201000062","volume":"2","author":"A Hoelbl","year":"2010","unstructured":"Hoelbl A, Schuster C, Kovacic B, Zhu B, Wickre M, Hoelzl MA, et al. Stat5 is indispensable for the maintenance of bcr\/abl\u2010positive leukaemia. EMBO Mol Med. 2010;2:98\u2013110.","journal-title":"EMBO Mol Med"},{"key":"1283_CR5","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1038\/leu.2009.49","volume":"23","author":"R Naughton","year":"2009","unstructured":"Naughton R, Quiney C, Turner SD, Cotter TG. Bcr-Abl-mediated redox regulation of the PI3K\/AKT pathway. Leukemia 2009;23:1432\u201340.","journal-title":"Leukemia"},{"key":"1283_CR6","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1158\/1078-0432.CCR-10-1613","volume":"18","author":"D Cilloni","year":"2012","unstructured":"Cilloni D, Saglio G. Molecular pathways: BCR-ABL. Clin Cancer Res. 2012;18:930\u20137.","journal-title":"Clin Cancer Res"},{"key":"1283_CR7","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1038\/leu.2011.66","volume":"25","author":"LS Steelman","year":"2011","unstructured":"Steelman LS, Franklin RA, Abrams SL, Chappell W, Kempf CR, B\u00e4secke J, et al. Roles of the Ras\/Raf\/MEK\/ERK pathway in leukemia therapy. Leukemia. 2011;25:1080\u201394.","journal-title":"Leukemia."},{"key":"1283_CR8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1756-8722-1-5","volume":"1","author":"KJ Baum","year":"2008","unstructured":"Baum KJ, Ren R. Effect of Ras inhibition in hematopoiesis and BCR\/ABL leukemogenesis. J Hematol Oncol. 2008;1:5.","journal-title":"J Hematol Oncol"},{"key":"1283_CR9","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1177\/107327480901600202","volume":"16","author":"LA Hazlehurst","year":"2009","unstructured":"Hazlehurst LA, Bewry NN, Nair RR, Pinilla-Ibarz J. Signaling networks associated with BCR-ABL-dependent transformation. Cancer Control. 2009;16:100\u20137.","journal-title":"Cancer Control"},{"key":"1283_CR10","doi-asserted-by":"publisher","first-page":"e963450","DOI":"10.4161\/23723548.2014.963450","volume":"1","author":"TS Ross","year":"2014","unstructured":"Ross TS, Mgbemena VE. Re-evaluating the role of BCR\/ABL in chronic myelogenous leukemia. Mol Cell Oncol. 2014;1:e963450.","journal-title":"Mol Cell Oncol"},{"key":"1283_CR11","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/ajh.25342","volume":"94","author":"J Cortes","year":"2019","unstructured":"Cortes J, Rea D, Lipton JH. Treatment-free remission with first- and second-generation tyrosine kinase inhibitors. Am J Hematol. 2019;94:346\u201357.","journal-title":"Am J Hematol"},{"key":"1283_CR12","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408\u201317.","journal-title":"N Engl J Med."},{"key":"1283_CR13","doi-asserted-by":"publisher","first-page":"939","DOI":"10.3389\/fonc.2019.00939","volume":"9","author":"F Loscocco","year":"2019","unstructured":"Loscocco F, Visani G, Galimberti S, Curti A, Isidori A. BCR-ABL independent mechanisms of resistance in chronic myeloid leukemia. Front Oncol. 2019;9:939.","journal-title":"Front Oncol"},{"key":"1283_CR14","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13045-018-0624-2","volume":"11","author":"F Rossari","year":"2018","unstructured":"Rossari F, Minutolo F, Orciuolo E. Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy. J Hematol Oncol. 2018;11:84.","journal-title":"J Hematol Oncol"},{"key":"1283_CR15","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","volume":"369","author":"JE Cortes","year":"2013","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369:1783\u201396.","journal-title":"N Engl J Med"},{"key":"1283_CR16","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1093\/carcin\/bgt111","volume":"34","author":"ME Murphy","year":"2013","unstructured":"Murphy ME. The HSP70 family and cancer. Carcinogenesis. 2013;34:1181\u20138.","journal-title":"Carcinogenesis."},{"key":"1283_CR17","doi-asserted-by":"publisher","first-page":"4153","DOI":"10.1038\/onc.2014.349","volume":"34","author":"MY Sherman","year":"2015","unstructured":"Sherman MY, Gabai VL. Hsp70 in cancer: back to the future. Oncogene. 2015;34:4153\u201361.","journal-title":"Oncogene."},{"key":"1283_CR18","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.canlet.2015.02.026","volume":"360","author":"GD Lianos","year":"2015","unstructured":"Lianos GD, Alexiou GA, Mangano A, Mangano A, Rausei S, Boni L, et al. The role of heat shock proteins in cancer. Cancer Lett. 2015;360:114\u20138.","journal-title":"Cancer Lett"},{"key":"1283_CR19","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.tips.2016.11.009","volume":"38","author":"J Wu","year":"2017","unstructured":"Wu J, Liu T, Rios Z, Mei Q, Lin X, Cao S. Heat shock proteins and cancer. Trends Pharm Sci. 2017;38:226\u201356.","journal-title":"Trends Pharm Sci"},{"key":"1283_CR20","first-page":"5761","volume":"62","author":"R Nimmanapalli","year":"2002","unstructured":"Nimmanapalli R, O\u2019Bryan E, Huang M. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, BcrAbl-positive, human acute leukemia cells retain sensitivity to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin (17-AAG). Cancer Res. 2002;62:5761\u20139.","journal-title":"Cancer Res"},{"key":"1283_CR21","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1182\/blood-2004-05-2041","volume":"105","author":"F Guo","year":"2005","unstructured":"Guo F, Sigua C, Bali P, George P, Fiskus W, Scuto A, et al. Mechanistic role of heat shock protein 70 in Bcr-Abl-mediated resistance to apoptosis in human acute leukemia cells. Blood. 2005;105:1246\u201355.","journal-title":"Blood."},{"key":"1283_CR22","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/sj.leu.2404463","volume":"21","author":"M Pocaly","year":"2007","unstructured":"Pocaly M, Lagarde V, Etienne G, Ribeil JA, Claverol S, Bonneu M, et al. Overexpression of the heat-shock protein 70 is associated to imatinib resistance in chronic myeloid leukemia. Leukemia. 2007;21:93\u2013101.","journal-title":"Leukemia."},{"key":"1283_CR23","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1016\/j.bbapap.2010.04.009","volume":"1804","author":"I Colavita","year":"2010","unstructured":"Colavita I, Esposito N, Martinelli R, Catanzano F, Melo JV, Pane F, et al. Gaining insights into the Bcr-Abl activity-independent mechanisms of resistance to imatinib mesylate in KCL22 cells: a comparative proteomic approach. Biochim Biophys Acta. 2010;1804:1974\u201387.","journal-title":"Biochim Biophys Acta"},{"key":"1283_CR24","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.3109\/10428194.2013.861070","volume":"55","author":"M Gonzalez","year":"2014","unstructured":"Gonzalez M, De Brasi C, Ferri C, Bengi\u00f3 R, Bianchini M, Larripa I. CAMKII\u03b3, HSP70 and HSP90 transcripts are differentially expressed in chronic myeloid leukemia cells from patients with resistant mutated disease. Leuk Lymphoma. 2014;55:2101\u20138.","journal-title":"Leuk Lymphoma"},{"key":"1283_CR25","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.canlet.2016.01.056","volume":"374","author":"S Kumar","year":"2016","unstructured":"Kumar S, Stokes J, Singh UP, Scissum Gunn K, Acharya A, Manne U, et al. Targeting Hsp70: a possible therapy for cancer. Cancer Lett. 2016;374:156\u201366.","journal-title":"Cancer Lett"},{"key":"1283_CR26","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1146\/annurev-pharmtox-010814-124332","volume":"55","author":"WB Pratt","year":"2015","unstructured":"Pratt WB, Gestwicki JE, Osawa Y, Lieberman AP. Targeting Hsp90\/Hsp70-based protein quality control for treatment of adult onset neurodegenerative diseases. Annu Rev Pharm Toxicol. 2015;55:353\u201371.","journal-title":"Annu Rev Pharm Toxicol"},{"key":"1283_CR27","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1083\/jcb.201709072","volume":"217","author":"CL Klaips","year":"2018","unstructured":"Klaips CL, Jayaraj GG, Hartl FU. Pathways of cellular proteostasis in aging and disease. J Cell Biol. 2018;217:51\u201363.","journal-title":"J Cell Biol"},{"key":"1283_CR28","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1111\/bph.14334","volume":"176","author":"B Rodriguez-Iturbe","year":"2019","unstructured":"Rodriguez-Iturbe B, Lanaspa MA, Johnson RJ. The role of autoimmune reactivity induced by heat shock protein 70 in the pathogenesis of essential hypertension. Br J Pharm. 2019;176:1829\u201338.","journal-title":"Br J Pharm"},{"key":"1283_CR29","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.chembiol.2015.12.006","volume":"23","author":"L Shrestha","year":"2016","unstructured":"Shrestha L, Patel HJ, Chiosis G. Chemical tools to investigate mechanisms associated with HSP90 and HSP70 in disease. Cell Chem Biol. 2016;23:158\u201372.","journal-title":"Cell Chem Biol"},{"key":"1283_CR30","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1021\/acs.jmedchem.8b00825","volume":"62","author":"M Ferraro","year":"2019","unstructured":"Ferraro M, D\u2019Annessa I, Moroni E, Morra G, Paladino A, Rinaldi S, et al. Allosteric modulators of HSP90 and HSP70: dynamics meets function through structure-based drug design. J Med Chem. 2019;62:60\u201387.","journal-title":"J Med Chem"},{"key":"1283_CR31","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1074\/jbc.TM118.002813","volume":"294","author":"JE Gestwicki","year":"2019","unstructured":"Gestwicki JE, Shao H. Inhibitors and chemical probes for molecular chaperone networks. J Biol Chem. 2019;294:2151\u201361.","journal-title":"J Biol Chem"},{"key":"1283_CR32","doi-asserted-by":"publisher","first-page":"253","DOI":"10.2174\/1568009619666191202101330","volume":"20","author":"J Sanchez","year":"2020","unstructured":"Sanchez J, Carter TR, Cohen MS, Blagg BSJ. Old and new approaches to target the Hsp90 chaperone. Curr Cancer Drug Targets. 2020;20:253\u201370.","journal-title":"Curr Cancer Drug Targets"},{"key":"1283_CR33","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/nchembio.670","volume":"7","author":"K Moulick","year":"2011","unstructured":"Moulick K, Ahn JH, Zong H, Rodina A, Cerchietti L, Gomes DaGama EM, et al. Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nat Chem Biol. 2011;7:818\u201326.","journal-title":"Nat Chem Biol"},{"key":"1283_CR34","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1182\/blood-2013-01-479972","volume":"122","author":"U Nayar","year":"2013","unstructured":"Nayar U, Lu P, Goldstein RL, Vider J, Ballon G, Rodina A, et al. Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies. Blood. 2013;122:2837\u201347.","journal-title":"Blood."},{"key":"1283_CR35","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.tips.2014.09.001","volume":"35","author":"T Taldone","year":"2014","unstructured":"Taldone T, Ochiana SO, Patel PD, Chiosis G. Selective targeting of the stress chaperome as a therapeutic strategy. Trends Pharm Sci. 2014;35:592\u2013603.","journal-title":"Trends Pharm Sci"},{"key":"1283_CR36","doi-asserted-by":"publisher","first-page":"4731","DOI":"10.1158\/0008-5472.CAN-14-0747","volume":"74","author":"TA Colvin","year":"2014","unstructured":"Colvin TA, Gabai VL, Gong J, Calderwood SK, Li H, Gummuluru S, et al. Hsp70-Bag3 interactions regulate cancer-related signaling networks. Cancer Res. 2014;74:4731\u201340.","journal-title":"Cancer Res"},{"key":"1283_CR37","doi-asserted-by":"publisher","first-page":"12900","DOI":"10.1074\/jbc.RA120.013364","volume":"295","author":"Z Guo","year":"2020","unstructured":"Guo Z, Song T, Wang Z, Lin D, Cao K, Liu P, et al. The chaperone Hsp70 is a BH3 receptor activated by the pro-apoptotic Bim to stabilize anti-apoptotic clients. J Biol Chem. 2020;295:12900\u20139.","journal-title":"J Biol Chem"},{"key":"1283_CR38","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1021\/jm101181u","volume":"54","author":"Z Zhang","year":"2011","unstructured":"Zhang Z, Wu G, Xie F, Song T, Chang X. 3-Thiomorpholin-8-oxo-8H-acenaphtho[1,2-b]pyrrole-9-carbonitrile (S1) based molecules as potent, dual inhibitors of B-cell lymphoma 2 (Bcl-2) and myeloid cell leukemia sequence 1 (Mcl-1): structure-based design and structure-activity relationship studies. J Med Chem. 2011;54:1101\u20135.","journal-title":"J Med Chem"},{"key":"1283_CR39","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1002\/cbic.201402639","volume":"16","author":"T Song","year":"2015","unstructured":"Song T, Yu X, Liu Y, Li X, Chai G, Zhang Z. Discovery of a small-molecule pBcl-2 inhibitor that overcomes pBcl-2-mediated resistance to apoptosis. Chembiochem. 2015;16:757\u201365.","journal-title":"Chembiochem."},{"key":"1283_CR40","doi-asserted-by":"publisher","first-page":"3948","DOI":"10.1182\/blood-2005-06-2209","volume":"106","author":"S Kimura","year":"2005","unstructured":"Kimura S, Naito H, Segawa H, Kuroda J, Yuasa T, Sato K, et al. NS-187, a potent and selective dual Bcr-Abl\/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood. 2005;106:3948\u201354.","journal-title":"Blood."},{"key":"1283_CR41","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.celrep.2012.07.007","volume":"2","author":"B Culjkovic-Kraljacic","year":"2012","unstructured":"Culjkovic-Kraljacic B, Baguet A, Volpon L, Amri A, Borden KL. The oncogene eIF4E reprograms the nuclear pore complex to promote mRNA export and oncogenic transformation. Cell Rep. 2012;2:207\u201315.","journal-title":"Cell Rep"},{"key":"1283_CR42","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.cell.2015.05.049","volume":"162","author":"ML Truitt","year":"2015","unstructured":"Truitt ML, Conn CS, Shi Z, Pang X, Tokuyasu T, Coady AM, et al. Differential requirements for eIF4E dose in normal development and cancer. Cell. 2015;162:59\u201371.","journal-title":"Cell"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01283-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01283-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01283-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T17:13:27Z","timestamp":1699031607000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-021-01283-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,18]]},"references-count":42,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["1283"],"URL":"https:\/\/doi.org\/10.1038\/s41375-021-01283-5","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,18]]},"assertion":[{"value":"5 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}